Ichnos Sciences aims to shift the way the world thinks about innovation in medicine by developing potentially transformative treatments in oncology. The company is fully integrated and has three sites—discovery research, including protein engineering, at Biopôle in Lausanne, Switzerland; biologics manufacturing and process sciences in La Chaux-de-Fonds, Switzerland; and company headquarters in the United States in New York, New York.
Ichnos has a broad multispecific oncology pipeline with five programs, including a clinical-stage first-in-class bispecific (CD38 x CD3) antibody for relapsed/refractory multiple myeloma (ISB 1342). The company’s proprietary BEAT® antibody engineering platform fuels the discovery engine to sustain innovation and drive long-term growth through creation of next generation multi-specific immune cell engagers and modulators. Beyond oncology, Ichnos has a pipeline of potential first-in-class therapeutics addressing autoimmune diseases available to out-license.
Officially launched on 15 October 2019, Ichnos has an experienced executive leadership team and board of directors. The company is a subsidiary of Glenmark Holding SA, which is currently funding operating expenses while additional investors are secured.